Table 2.
Characteristics of patients with HCC in each treatment group with C-P sores of 12–15
| Background factors | BSC | LAT | TACE | Total | p value |
|---|---|---|---|---|---|
| n=1040 | |||||
| n=93 | n=22 | n=28 | n=143 | ||
| No. of Patients | No. of Patients | No. of Patients | No. of Patients | ||
| Age (years) | |||||
| <60 | 26 | 8 | 12 | 46 | 0.320 |
| ≥60 | 67 | 14 | 16 | 97 | |
| Sex | |||||
| Male | 60 | 17 | 19 | 96 | 0.516 |
| Female | 33 | 5 | 9 | 47 | |
| Hepatitis B and C virological status | |||||
| B−, C+ | 47 | 14 | 19 | 80 | 0.134 |
| B+, C− | 15 | 3 | 3 | 21 | |
| B+, C+ | 1 | 1 | 1 | 3 | |
| B−, C− | 24 | 4 | 5 | 33 | |
| Maximum tumor size (cm) | |||||
| ≤2.0 | 38 | 13 | 10 | 61 | 0.489 |
| 2.1–3.0 | 35 | 7 | 12 | 54 | |
| 3.1–5.0 | 20 | 2 | 6 | 28 | |
| No. of tumors | |||||
| 1 | 66 | 18 | 20 | 104 | 0.392 |
| ≥2 | 27 | 4 | 8 | 39 | |
| AFP (ng/ml) | |||||
| ≤200 | 47 | 7 | 25 | 79 | 0.090 |
| >200 | 54 | 7 | 12 | 73 | |
| TNM stage | |||||
| I | 24 | 10 | 6 | 40 | 0.362 |
| II | 56 | 11 | 18 | 85 | |
| III | 13 | 1 | 4 | 18 | |